跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 41 条关于
“Crexont”
全部
41
临床试验
26
药物
0
机构
1
资讯
14
去年
Amneal's CREXONT Shows Significant Sleep Quality Improvements in Parkinson's Disease Patients
2年前
FDA Approves Crexont for Parkinson's Disease Treatment
9个月前
Amneal's CREXONT Shows Significant Clinical Benefits in Phase 4 Parkinson's Disease Study
2年前
FDA Approves Crexont (IPX203) for Parkinson's Disease with USF Researcher's Contribution
去年
Knight Therapeutics Files New Drug Submission for CREXONT in Canada Following Successful Phase 3 Trial
5个月前
CREXONT Shows Superior Efficacy in Phase 4 Trial, Delivering Over 3 Additional Hours of Daily "Good On" Time for Parkinson's Patients
去年
FDA Approves Amneal's Extended-Release Pyridostigmine Bromide Tablets for Nerve Agent Pretreatment
去年
Amneal's Pyridostigmine Bromide Extended-Release Tablets Receive FDA Approval for Nerve Agent Pretreatment
去年
Amneal Pharmaceuticals Reports Strong Q1 2025 Results with 5% Revenue Growth and Margin Expansion
去年
Amneal Pharmaceuticals Reports 18% Revenue Growth, Expands into Weight Loss and Biosimilar Markets
第 1 页,共 2 页
上一页
下一页